Royalty Payment Term. Subject to the cumulative royalty cap specified in Section 8.07.6, ExxonMobil's obligation to pay license royalties to Symyx Tech shall continue for each Royalty-Bearing Product until *.
Royalty Payment Term. The obligation of Purchaser to make payments under Sections 3.1 and 3.2 shall continue, on a Product-by-Product and country-by-country basis, until the 15th anniversary of the first commercial sale of such Product in such country.
Royalty Payment Term. Pfizer shall pay Isis a royalty based on the Net Sales of each Licensed Product.
3.1.1 In countries in which such Licensed Product is covered by a Valid Claim in Program Technology Patent Rights, Isis Technology Patent Rights, [***] or Isis Licensed Technology Patent Rights, a royalty shall be paid with respect to each such country from the date of first commercial sale (the date of the invoice of Pfizer or any sublicense of Pfizer with respect to such sale) of such Licensed Product in such country until the date on which such Licensed Product is no longer covered by a Valid Claim in Program Technology Patent Rights, Isis Technology Patent Rights, [***] or Isis Licensed Technology Patent Rights in such country (“Royalty Payment Term”).
3.1.2 If a Licensed Product is sold in countries in which such Licensed Product is not covered by a Valid Claim in Program Technology Patent Rights, Isis Technology Patent Rights, [***] or Isis Licensed Technology Patent Rights, and such Licensed Product is manufactured in a country in which it is covered by a Valid Claim in Program Technology Patent Rights, Isis Technology Patent Rights, [***] or Isis Licensed Technology Patent Rights, Pfizer shall pay Isis a [***] royalty based on the Net Sales of such Licensed Product pursuant to Section 3.2.2.
Royalty Payment Term. The above royalties shall be payable for each Product in each country of the Sanofi Territory until the later to occur of (i) the expiration of the last to expire Valid Claim within the Vivus Patents that, absent the licenses granted to Sanofi hereunder, would be infringed by the sale of such Product in such country, and (ii) the sixteenth anniversary of the Effective Date (the “Royalty Payment Term”).
Royalty Payment Term. “Royalty Payment Term” shall have the meaning assigned to such term in the Royalty Agreement.
Royalty Payment Term. The obligation of Licensee to make payments under Sections 4.1 and 4.2 shall continue, on a Licensed Product-by-Licensed Product and country-by-country basis, until the later of (i) the date on which the offering for sale, selling, making, having made, using, or importing such Licensed Product is no longer covered by a Valid Claim of a Licensed Patent in such country and (ii) the 15th anniversary of the first commercial sale of such Licensed Product in such country. [****] The following portion has been omitted pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.
Royalty Payment Term. Payment term will begin with the effective date of the first royalty payment as expressed in Article 6 and continue for a period of seven additional years after which time payments will cease
Royalty Payment Term. Immunic’s obligation to make royalty payments terminates on a country-by-country and Licensed Product-by-Licensed Product basis by the later of (i) the Licensed Product is no longer covered by a Valid Claim in an issued patent within the DS Patent Rights in the relevant country, or (ii) [***] after the First Commercial Sale of the respective Licensed Product in the relevant country; provided, however, that if the Licensed Product:
(a) is no longer covered by a Valid Claim in an issued patent within the DS Patent Rights in the relevant country,
(b) no longer enjoys market exclusivity from legal or regulatory protections (e.g. data exclusivity) obtained by the original holder of the Regulatory Approval in the relevant country, and
(c) one or more generic competitors enter the market in the relevant country and as a result, the prescription volume of the Licensed Product declines by [***] or more in such country. For the purposes of this Section 6.6(c), the decline in prescription volume shall be measured by comparing the total number of units sold by Immunic, its Affiliates, and sub-licensees during the applicable calendar quarter against the average of the total number of units sold by Immunic, its Affiliates, and sub-licensees during the [***] immediately before the first sale of a product by the first generic competitor in such country, then the royalty rate shall be reduced to [***] for Net Sales of such Licensed Product in the relevant country.
Royalty Payment Term. The above royalties shall be payable from the Transition Date until the [* * *] anniversary of the Transition Date (the “Royalty Term”), irrespective of [* * *]. By way of illustration, [* * *].
Royalty Payment Term. The obligations of GSK to calculate and make royalty payments as set forth in Section 8.3 above will commence upon the First Commercial Sale of the Licensed Product in the Territory by GSK, its Affiliates, sublicensees or Excluded Distributors and will continue for the Term.
